Zhitong Financial App News, Changjiang Life Technology (00775.HK) announced that Sequencio Therapeutics Company Limited (“Shunpu Pharmaceutical Technology”), a wholly-owned subsidiary of the company, will present the latest research data on its leading cancer vaccine projects at the 2026 Annual Meeting of the Society for Cancer Immunotherapy (SITC) in Phoenix, Arizona, USA, respectively, the TROP2 circRNA-LNP vaccine and PD-L1/ PRAME dual antigen vaccine.

Zhitongcaijing · 2d ago
Zhitong Financial App News, Changjiang Life Technology (00775.HK) announced that Sequencio Therapeutics Company Limited (“Shunpu Pharmaceutical Technology”), a wholly-owned subsidiary of the company, will present the latest research data on its leading cancer vaccine projects at the 2026 Annual Meeting of the Society for Cancer Immunotherapy (SITC) in Phoenix, Arizona, USA, respectively, the TROP2 circRNA-LNP vaccine and PD-L1/ PRAME dual antigen vaccine.